Publication
Navigating Antibody-Drug Conjugate Sequencing in Gastric Cancer: Cross-Resistance Biology, Target Switching, and Decision-Making Frameworks for the Post-Progression Landscape.
Yue Wu
Current oncology reportsSep 8, 2026PMID 42709339doi:10.1007/s11912-026-01826-y Journal ArticleReviewpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 13, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260913-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) have reshaped the therapeutic landscape of advanced gastric cancer, with trastuzumab deruxtecan (T-DXd) and disitamab vedotin (RC48) establishing new standards for HER2-positive disease, and a wave of Claudin 18.2 (CLDN18.2)-directed ADCs…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.